surpass 6 tirzepatide Safety and efficacy of as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan ( J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial A) The SURPASS Program (SURPASS1–6).
Pay in 4 interest-free payments of $7.12 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25





























